Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/nejmc1714146 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura.
Br J Haematol
July 2022
Department of Haematology, University College Hospitals London NHS Foundation Trust, London, UK.
Rituximab, an anti-CD20 monoclonal antibody, can be used to treat immune thrombotic thrombocytopenic purpura (iTTP) during acute presentation or disease relapse. Undesirable side-effects include severe hypersensitivity reactions, particularly anaphylaxis and rituximab-induced serum sickness, with a minority not maintaining a response to treatment. Alternative humanised anti-CD20 treatments, obinutuzumab and ofatumumab, have been used.
View Article and Find Full Text PDFMore on Ofatumumab for TTP.
N Engl J Med
April 2018
University College London Hospitals, London, United Kingdom
Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura.
J Thromb Thrombolysis
July 2018
Division of Hematology, Brigham and Women's Hospital, Boston, USA.
Acquired thrombotic thrombocytopenic purpura (TTP) is an autoimmune disorder resulting in potentially life-threating systemic thrombotic microangiopathy due to production of antibodies directed against the von Willebrand factor-cleaving protease ADAMTS13. Typically managed with plasma exchange, glucocorticoids, and the first-generation anti-CD20 monoclonal antibody rituximab, patients with multiple relapses or refractory disease present unique management challenges. We describe a case of a young woman with multiple relapses of TTP despite standard therapy who was treated with ofatumumab, a second-generation anti-CD20 monoclonal antibody, after developing a severe hypersensitivity reaction to rituximab precluding its use.
View Article and Find Full Text PDFOfatumumab for TTP in a Patient with Anaphylaxis Associated with Rituximab.
N Engl J Med
January 2018
University College London Hospitals, London, United Kingdom.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!